Galectin Therapeutics Ownership | Who Owns Galectin Therapeutics?


OverviewForecastFinancialsChart

Galectin Therapeutics Ownership Summary


Galectin Therapeutics is owned by 23.94% institutional investors, 53.08% insiders, and 22.98% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 4.54% of GALT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.31% of its assets in Galectin Therapeutics shares.

GALT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockGalectin Therapeutics23.94%53.08%22.98%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de2.99M4.54%$13.87M
Vanguard group2.29M3.56%$9.52M
Vanguard capital management2.17M3.30%$10.06M
Blackrock1.56M2.52%$3.53M
Geode capital management1.31M1.99%$6.07M
Advisor group1.20M1.83%$5.59M
Marshall wace, llp831.01K1.26%$3.86M
Wealthspire advisors721.79K1.10%$3.35M
State street567.78K0.86%$2.63M
Commonwealth equity services407.11K0.62%$1.89M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Retirement guys formula211.05K0.37%$979.29K
Solutions 4 wealth25.03K0.15%$116.13K
Vivaldi capital management lp258.58K0.10%$721.45K
Sovran advisors258.00K0.07%$874.61K
Argyle capital partners13.38K0.04%$62.06K
Gsa capital partners llp128.66K0.04%$597.00K
Geneos wealth management240.43K0.02%$1.12M
Wealthspire advisors721.79K0.02%$3.35M
Archer investment17.40K0.02%$80.74K
Pekin hardy strauss30.00K0.01%$139.20K

Top Buyers

HolderShares% AssetsChange
Blackrock funding, inc. /de2.99M0.00%2.19M
Blackrock1.56M0.00%851.14K
Geode capital management1.31M0.00%695.61K
State street567.78K0.00%309.35K
Northern trust386.55K0.00%256.10K

Top Sellers

HolderShares% AssetsChange
Millennium management35.86K0.00%-762.57K
Marshall wace, llp831.01K0.00%-388.90K
Susquehanna group, llp177.20K0.00%-378.50K
Y-intercept (hong kong)---235.19K
Jane street group---194.87K

New Positions

HolderShares% AssetsChangeValue
National bank of canada /fi/167.90K0.00%167.90K$779.06K
Sixth street partners management company116.42K0.00%116.42K$540.21K
Bank of new york mellon105.74K0.00%105.74K$490.64K
Nuveen63.71K0.00%63.71K$295.61K
Rhumbline advisers48.33K0.00%48.33K$224.26K

Sold Out

HolderChange
Eversource wealth advisors-1.00
True wealth design-2.00
Sbi securities-5.00
Srs capital advisors-52.00
Harbour investments-150.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20261060.95%15,749,02213.53%235.38%555.77%23-4.17%
Mar 31, 202644-56.86%5,526,312-52.22%82.67%22-59.26%9-59.09%
Dec 31, 202569-22.47%8,887,115-13.85%135.24%32-11.11%17-37.04%
Sep 30, 202587-3.33%10,009,146-4.34%155.76%35-5.41%2618.18%
Jun 30, 202588-7.37%9,965,1580.59%156.42%3624.14%22-26.67%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.52M2.31%170.00K
Vanguard Morn Total Stk Mkt Idx Investor1.52M2.31%170.00K
Vanguard US Total Market Shares ETF1.25M1.97%-
iShares Russell 2000 ETF1.04M1.58%-18.43K
Vanguard MStar Total Stk Mkt Idx Invest1.52M1.51%-
Vanguard Institutional Extnd Mkt Idx Tr618.82K0.61%23.67K
iShares Russell 2000 Growth ETF302.35K0.46%-2.77K
Russell 2000 Index Non-Lendable Fund288.97K0.44%288.97K
Russell 2000 Equity Index Fund B288.97K0.44%288.97K
Fidelity Extended Market Index274.30K0.42%2.71K

Recent Insider Transactions


DateNameRoleActivityValue
Jul 14, 2026Jamil Khurram Chief Medical OfficerSell$83.28K
Jun 29, 2026Shlevin Harold H.-Sell$112.23K
Jun 26, 2026Shlevin Harold H.-Sell$38.66K
Jun 26, 2026Jamil Khurram Chief Medical OfficerSell$12.66K
Jun 29, 2026Jamil Khurram Chief Medical OfficerSell$239.23K

Insider Transactions Trends


DateBuySell
2026 Q3-1
2026 Q2-6
2026 Q119
2025 Q4239
2025 Q322

GALT Ownership FAQ


Who Owns Galectin Therapeutics?

Galectin Therapeutics shareholders are primarily institutional investors at 23.94%, followed by 53.08% insiders and 22.98% retail investors. The average institutional ownership in Galectin Therapeutics's industry, Biotech Stocks , is 379.61%, which Galectin Therapeutics falls below.

Who owns the most shares of Galectin Therapeutics?

Galectin Therapeutics’s largest shareholders are Blackrock funding, inc. /de (2.99M shares, 4.54%), Vanguard group (2.29M shares, 3.56%), and Vanguard capital management (2.17M shares, 3.30%). Together, they hold 11.40% of Galectin Therapeutics’s total shares outstanding.

Does Blackrock own Galectin Therapeutics?

Yes, BlackRock owns 2.52% of Galectin Therapeutics, totaling 1.56M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.53M$. In the last quarter, BlackRock increased its holdings by 851.14K shares, a 119.44% change.

Who is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested?

Retirement guys formula is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.37% of its assets in 211.05K Galectin Therapeutics shares, valued at 979.29K$.

Who is the top mutual fund holder of Galectin Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Galectin Therapeutics shares, with 2.31% of its total shares outstanding invested in 1.52M Galectin Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools